314.15
+2.60%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ligand Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Ligand Pharmaceuticals is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker LGND. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $268.1m and net income of $124.5m. At that date it held total assets of $1.56bn and shareholders' equity of $1.02bn.
We are a biopharmaceutical royalty company focused on deploying capital and licensing technologies to acquire and create diversified royalty streams from high-value medicines. Our primary business is investing in and structuring royalty interests in mid- to late-stage development and commercial biopharmaceutical products, allowing us to generate long-duration, non-dilutive cash flows supported by a lean corporate cost structure. Capital deployment and technology licensing are the primary drivers of our long-term growth.
We partner capital through a range of transaction structures—including royalty purchases, development-stage financing arrangements, and acquisitions of companies or assets with embedded royalty rights—designed to create cash flowing royalties and produce attractive risk-adjusted returns. Our goal is to provide investors with exposure to biopharmaceutical innovation through a diversified portfolio of royalty interests while mitigating the binary risk and capital intensity traditionally associated with drug development.
In addition to our royalty investment activities, we operate two infrastructure-light, royalty-generating platform technologies, Captisol® and NITRICIL®. These technologies exemplify our platform technology investment criteria: infrastructure-light, scalable intellectual property with existing royalty streams and the potential to generate incremental royalties through partner-driven development and commercialization.
Quoted from its 10-K, filed 27 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 18 Nov 1992
- Employees
- 47
- Website
- ligand.com ↗
- Head office
- 3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA, 92121
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. John KozarichIndependent Chairman of the Board$374,913
- Mr. Todd DavisChief Executive Officer, Director, since 2007$12.9m
- Mr. Octavio EspinozaChief Financial Officer$3.3m
- Mr. Andrew ReardonChief Legal Officer$3.3m
- Mr. Jason AryehIndependent Director$352,413
- Dr. Nancy GrayIndependent Director$349,913
- Mr. Jason HaasIndependent Director$359,913
- Dr. John LamattinaIndependent Director$342,413
- Dr. Stephen SabbaIndependent Director$354,913
- Dr. Martine ZimmermannIndependent Director$339,913
- Ms. Melanie HermanInvestor Relations$632,615
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 31
- Environment
- 21
- Social
- 24
- Governance
- 46
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ligand Pharmaceuticals Inc possesses several strengths that contribute to its success in the pharmaceutical industry. These strengths include:
Weaknesses
- Despite its strengths, Ligand Pharmaceuticals Inc also faces certain weaknesses that can hinder its growth. These weaknesses include:
Opportunities
- Ligand Pharmaceuticals Inc can leverage various opportunities to further expand its market presence and drive growth. These opportunities include:
Threats
- Ligand Pharmaceuticals Inc operates in a highly competitive and regulated industry, facing several threats that could impact its success. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.